PMID- 26613006
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151127
LR  - 20220330
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 7
DP  - 2015
TI  - The association of circulating levels of complement-C1q TNF-related protein 5 
      (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control 
      study.
PG  - 108
LID - 10.1186/s13098-015-0099-z [doi]
LID - 108
AB  - BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) 
      is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related 
      protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and 
      glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with 
      NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in 
      comparison with healthy subjects (n = 21) and also to study the association 
      between CTRP5 levels and NAFLD and diabetes-related parameters. METHODS: All 
      subjects underwent anthropometric assessment, biochemical evaluation and liver 
      stiffness (LS) measurement. Insulin resistance (IR) was determined by the 
      homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by 
      enzyme-linked immunosorbent assay. RESULTS: We found significantly lower plasma 
      levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 +/- 1.92, 
      124.7 +/- 1.82 and 118.31 +/- 1.99 ng/ml, respectively) in comparison with controls 
      (164.96 +/- 2.95 ng/ml). In the whole study population, there was a significant 
      negative correlations between CTRP5 and body mass index (r = -0.337; p = 0.002), 
      fasting blood glucose (FBG) (r = -0.488; p < 0.001), triglyceride (TG) 
      (r = -0.245; p = 0.031), HOMA-IR (r = -0.492; p < 0.001), insulin(r = -0.338; 
      p = 0.002), LS (r = -0.544; p < 0.001), alanine aminotransferase (ALT) 
      (r = -0.251; p = 0.027), waist-to-hip ratio (WHR) (r = -0.352; p = 0.002) and 
      waist circumference (WC) (r = -0.357; p = 0.001). After adjustment for BMI, 
      decrease in circulating levels of CTRP5 remained as a significant risk factor for 
      NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves 
      of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the 
      curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM. CONCLUSIONS: It appears 
      that the decreased levels of CTRP5 contribute to the increased risk of T2DM and 
      NAFLD.
FAU - Emamgholipour, Solaleh
AU  - Emamgholipour S
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Moradi, Nariman
AU  - Moradi N
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Iran University of 
      Medical Sciences, Tehran, Iran.
FAU - Beigy, Maani
AU  - Beigy M
AD  - Students' Scientific Research Center, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Shabani, Parisa
AU  - Shabani P
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Fadaei, Reza
AU  - Fadaei R
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Poustchi, Hossein
AU  - Poustchi H
AD  - Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Doosti, Mahmood
AU  - Doosti M
AD  - Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of 
      Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20151125
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC4660841
OTO - NOTNLM
OT  - CTRP5
OT  - Insulin resistance
OT  - Nonalcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
EDAT- 2015/11/28 06:00
MHDA- 2015/11/28 06:01
PMCR- 2015/11/25
CRDT- 2015/11/28 06:00
PHST- 2015/05/27 00:00 [received]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2015/11/28 06:00 [entrez]
PHST- 2015/11/28 06:00 [pubmed]
PHST- 2015/11/28 06:01 [medline]
PHST- 2015/11/25 00:00 [pmc-release]
AID - 99 [pii]
AID - 10.1186/s13098-015-0099-z [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2015 Nov 25;7:108. doi: 10.1186/s13098-015-0099-z. 
      eCollection 2015.